Uplisting Eligibility Checker: OTC to Nasdaq

The uplisting sequence, in the order it actually happens

Uplisting is a corporate action, not a paperwork exercise — it moves an already-public OTC company's existing shares onto a national exchange rather than issuing new ones for the first time. The sequence that actually works starts with the audit, not the application. Most OTC issuers, especially long-tenured Pink or OTCQB companies, are carrying financials that were audited to a lighter standard, or audited inconsistently across fiscal years. A PCAOB-standard re-audit that can withstand Nasdaq Listing Qualifications scrutiny is the first gate, and it's the one founders most consistently underestimate — a clean re-audit routinely takes two to three reporting cycles to fully settle, not one engagement letter.

Governance comes next, and it runs in parallel with the audit rather than after it. Nasdaq requires a majority-independent board, an independent audit committee with a designated financial expert, and functioning compensation and nominating committees. Companies that have operated OTC for years with a founder-controlled, non-independent board need real time to recruit qualified independent directors, adopt committee charters, and build a documented track record of those committees actually meeting — a board added the month before filing reads as exactly that to Nasdaq staff.

Only once the audit and governance work is underway does the market mechanics track start: seasoning the bid price at or above $4.00, verifying the true count of round-lot holders, and lining up the 3 registered market makers Nasdaq requires. All three of those depend on trading activity that can't be manufactured overnight, which is why the runway below runs closer to a year than a quarter.

Why most uplisting attempts stall

The single most common stall point isn't a hard rule — it's MVPHS. Market value of publicly held shares excludes affiliate and restricted holdings, so a company with a large headline share count and a decent bid price can still fall well short of the $15M MVPHS floor that all three standards share, because most of the float sits with insiders. Fixing that means either growing the genuinely free-trading float or raising the price of the shares that are already free-trading — neither happens quickly, and neither is solved by the reverse split that fixes the bid-price test.

The second most common stall point is cost sequencing. Between the audit uplift, governance buildout, legal work, and Nasdaq's own $50K–$75K entry fee plus an ongoing $56K–$86.5K annual fee, issuers frequently run out of runway budget before the application is even submitted, because they costed the fee schedule but not the year of legal, audit, and IR spend that has to happen first. Third, and least visible from the outside: market maker relationships. Three willing, active market makers isn't a checkbox — it's a relationship built over months of actual trading volume and issuer responsiveness, and issuers who start that conversation only after everything else is ready lose the most calendar time of the whole process waiting on it.

The bid-price seasoning reality

Clearing $4.00 once, on the day you file, is not the same as clearing it. Nasdaq's practice — not a single codified rule — is to want that price sustained for something like 30 of the most recent 60 trading days, with a 5-consecutive-day closing-bid check applied right before approval. A reverse split gets you to $4.00 in a single corporate action; it does not get you through 60 trading days of holding it there, and thin OTC liquidity means a stock that splits to exactly $4.00 has very little room to drift before it's back under the line. The practical implication: run the split early enough, and with enough cushion above the minimum, that a normal amount of OTC volatility doesn't reset the seasoning clock the week before you file.

The same split also interacts with the round-lot holder count in a way that trips up issuers who treat it as pure arithmetic. Post-split share counts get rounded up for fractional shares, and that rounding can make the holder count look cured on paper without actually converting enough beneficial owners into genuine 100-share-plus round-lot holders. Verify the post-split number directly with your transfer agent's shareholder records, not by dividing your pre-split holder count by the split ratio.

Worked example

Take the default numbers loaded into the checker above: an OTC company with 38,000,000 shares outstanding, a $2.35 bid, $4.6M of stockholders' equity, $410,000 of trailing net income, and an MVPHS estimate of $13.2M. Run those through all three standards and the Market Value Standard comes out closest: the $4M equity floor already clears (equity sits at $4.6M), the $50M market-value-of-listed-securities test clears comfortably at roughly $89.3M (38,000,000 shares × $2.35), and the only real gap is MVPHS — about $1.8M short of the $15M bar. That's a meaningfully smaller lift than the Net Income Standard, where the same company is short on both MVPHS and net income (which sits under the $750K threshold), or the Equity Standard, where the higher $5M equity floor adds another six-figure gap on top of the same MVPHS shortfall.

None of that touches the bid price, though. At $2.35, this company needs roughly a 1-for-1.70 reverse split just to reach $4.00 exactly — in practice, a company in this position would size the split for a cushion above $4.00 and start the market maker conversation well before the seasoning clock even starts running, which is exactly what the runway checklist above is built to sequence.